Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | LEGN |
---|---|---|
09:32 ET | 21318 | 46.33 |
09:34 ET | 300 | 46.36 |
09:36 ET | 132 | 46.21 |
09:38 ET | 200 | 46.16 |
09:39 ET | 3996 | 46.4975 |
09:41 ET | 13424 | 46.59 |
09:43 ET | 14885 | 47.29 |
09:45 ET | 17573 | 46.56 |
09:48 ET | 19191 | 46.7451 |
09:50 ET | 13041 | 46.74 |
09:52 ET | 8053 | 46.5726 |
09:54 ET | 5660 | 46.27 |
09:56 ET | 1410 | 46.11 |
09:57 ET | 1300 | 45.83 |
09:59 ET | 140 | 45.862 |
10:01 ET | 5149 | 45.605 |
10:03 ET | 11091 | 45.38 |
10:06 ET | 9128 | 45.58 |
10:08 ET | 538 | 45.77 |
10:10 ET | 2332 | 46.02 |
10:12 ET | 700 | 46.02 |
10:14 ET | 509 | 46.04 |
10:15 ET | 300 | 45.945 |
10:17 ET | 3940 | 45.785 |
10:19 ET | 1000 | 45.72 |
10:21 ET | 1611 | 46.03 |
10:24 ET | 200 | 46.12 |
10:26 ET | 407 | 46.045 |
10:28 ET | 1300 | 45.99 |
10:30 ET | 1087 | 46.08 |
10:32 ET | 1423 | 46.13 |
10:33 ET | 803 | 46.02 |
10:35 ET | 387 | 46.03 |
10:37 ET | 700 | 45.9 |
10:39 ET | 300 | 45.88 |
10:42 ET | 400 | 45.915 |
10:44 ET | 2229 | 45.73 |
10:46 ET | 400 | 45.77 |
10:48 ET | 1800 | 45.55 |
10:50 ET | 300 | 45.535 |
10:51 ET | 752 | 45.54 |
10:53 ET | 700 | 45.565 |
10:55 ET | 3700 | 45.42 |
10:57 ET | 1355 | 45.58 |
11:00 ET | 2622 | 45.53 |
11:02 ET | 200 | 45.705 |
11:06 ET | 1901 | 45.64 |
11:08 ET | 9049 | 45.6 |
11:09 ET | 900 | 45.5 |
11:11 ET | 600 | 45.425 |
11:13 ET | 600 | 45.28 |
11:15 ET | 6590 | 45.34 |
11:18 ET | 400 | 45.485 |
11:22 ET | 1171 | 45.48 |
11:24 ET | 308 | 45.48 |
11:26 ET | 621 | 45.53 |
11:27 ET | 500 | 45.49 |
11:29 ET | 100 | 45.435 |
11:31 ET | 835 | 45.47 |
11:33 ET | 900 | 45.43 |
11:36 ET | 200 | 45.43 |
11:38 ET | 2101 | 45.46 |
11:40 ET | 400 | 45.52 |
11:42 ET | 100 | 45.54 |
11:44 ET | 100 | 45.54 |
11:45 ET | 2390 | 45.49 |
11:47 ET | 2859 | 45.385 |
11:49 ET | 366 | 45.395 |
11:51 ET | 1279 | 45.355 |
11:54 ET | 9815 | 45.51 |
11:56 ET | 2700 | 45.52 |
11:58 ET | 100 | 45.505 |
12:00 ET | 1604 | 45.51 |
12:02 ET | 300 | 45.53 |
12:03 ET | 100 | 45.54 |
12:05 ET | 38056 | 45.5 |
12:07 ET | 5570 | 45.58 |
12:09 ET | 200 | 45.59 |
12:12 ET | 300 | 45.6 |
12:14 ET | 500 | 45.61 |
12:16 ET | 2827 | 45.5 |
12:18 ET | 8010 | 45.51 |
12:20 ET | 619 | 45.505 |
12:21 ET | 300 | 45.505 |
12:23 ET | 1600 | 45.53 |
12:25 ET | 300 | 45.51 |
12:27 ET | 10289 | 45.47 |
12:30 ET | 20253 | 45.31 |
12:32 ET | 600 | 45.27 |
12:34 ET | 3120 | 45.07 |
12:36 ET | 1125 | 45.13 |
12:38 ET | 2601 | 45.04 |
12:39 ET | 3108 | 45.15 |
12:41 ET | 18089 | 45.14 |
12:43 ET | 5843 | 45.19 |
12:45 ET | 200 | 45.23 |
12:48 ET | 400 | 45.22 |
12:50 ET | 100 | 45.26 |
12:52 ET | 2503 | 45.26 |
12:54 ET | 1488 | 45.23 |
12:56 ET | 1410 | 45.26 |
12:57 ET | 1212 | 45.23 |
12:59 ET | 1000 | 45.25 |
01:01 ET | 2610 | 45.21 |
01:03 ET | 10436 | 44.99 |
01:06 ET | 754 | 44.985 |
01:08 ET | 2795 | 45.225 |
01:10 ET | 1483 | 45.27 |
01:12 ET | 1914 | 45.2 |
01:14 ET | 1193 | 45.235 |
01:15 ET | 1100 | 45.27 |
01:17 ET | 924 | 45.28 |
01:19 ET | 1804 | 45.26 |
01:21 ET | 900 | 45.26 |
01:24 ET | 9735 | 45.14 |
01:26 ET | 2802 | 45.2 |
01:28 ET | 900 | 45.07 |
01:30 ET | 2051 | 44.988 |
01:32 ET | 9003 | 44.7701 |
01:33 ET | 4958 | 44.88 |
01:35 ET | 800 | 44.97 |
01:37 ET | 715 | 45.0512 |
01:39 ET | 1110 | 44.88 |
01:42 ET | 1305 | 44.935 |
01:44 ET | 400 | 44.94 |
01:46 ET | 392 | 44.97 |
01:48 ET | 1500 | 44.9 |
01:50 ET | 11596 | 44.84 |
01:51 ET | 2220 | 44.85 |
01:53 ET | 1664 | 44.685 |
01:55 ET | 600 | 44.73 |
01:57 ET | 400 | 44.81 |
02:00 ET | 3072 | 44.703 |
02:02 ET | 1000 | 44.76 |
02:04 ET | 453 | 44.74 |
02:06 ET | 3426 | 44.86 |
02:08 ET | 2978 | 44.855 |
02:09 ET | 1100 | 44.8 |
02:11 ET | 523 | 44.775 |
02:13 ET | 3978 | 44.62 |
02:15 ET | 300 | 44.595 |
02:18 ET | 815 | 44.57 |
02:20 ET | 2049 | 44.66 |
02:22 ET | 200 | 44.64 |
02:24 ET | 1350 | 44.625 |
02:26 ET | 3250 | 44.598 |
02:27 ET | 765 | 44.61 |
02:29 ET | 8445 | 44.68 |
02:31 ET | 5984 | 44.7781 |
02:33 ET | 2045 | 44.7 |
02:36 ET | 2521 | 44.69 |
02:38 ET | 2786 | 44.755 |
02:40 ET | 2168 | 44.81 |
02:42 ET | 2146 | 44.795 |
02:44 ET | 700 | 44.84 |
02:45 ET | 4767 | 44.82 |
02:47 ET | 2417 | 44.8 |
02:49 ET | 1102 | 44.745 |
02:51 ET | 548 | 44.735 |
02:54 ET | 300 | 44.69 |
02:56 ET | 1450 | 44.67 |
02:58 ET | 595 | 44.67 |
03:00 ET | 3455 | 44.69 |
03:02 ET | 300 | 44.675 |
03:03 ET | 1354 | 44.66 |
03:05 ET | 700 | 44.68 |
03:07 ET | 1180 | 44.74 |
03:09 ET | 1800 | 44.815 |
03:12 ET | 2103 | 44.79 |
03:14 ET | 969 | 44.71 |
03:16 ET | 929 | 44.68 |
03:18 ET | 983 | 44.75 |
03:20 ET | 1875 | 44.8411 |
03:21 ET | 600 | 44.8 |
03:23 ET | 1664 | 44.785 |
03:25 ET | 652 | 44.8 |
03:27 ET | 200 | 44.785 |
03:30 ET | 2044 | 44.82 |
03:32 ET | 1448 | 44.805 |
03:34 ET | 1250 | 44.75 |
03:36 ET | 3830 | 44.695 |
03:38 ET | 700 | 44.69 |
03:39 ET | 2409 | 44.635 |
03:41 ET | 4240 | 44.64 |
03:43 ET | 1500 | 44.67 |
03:45 ET | 2298 | 44.68 |
03:48 ET | 6664 | 44.8075 |
03:50 ET | 9533 | 44.79 |
03:52 ET | 11029 | 44.65 |
03:54 ET | 7394 | 44.8 |
03:56 ET | 11834 | 44.71 |
03:57 ET | 12882 | 44.735 |
03:59 ET | 82490 | 44.74 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Legend Biotech Corp | 8.2B | -17.2x | --- |
Ascendis Pharma A/S | 7.9B | -14.3x | --- |
Blueprint Medicines Corp | 6.9B | -22.9x | --- |
Vaxcyte Inc | 8.3B | -18.0x | --- |
Intra-Cellular Therapies Inc | 7.2B | -59.5x | --- |
Insmed Inc | 10.5B | -12.3x | --- |
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.2B |
---|---|
Revenue (TTM) | $342.8M |
Shares Outstanding | 182.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.11 |
EPS | $-2.60 |
Book Value | $6.88 |
P/E Ratio | -17.2x |
Price/Sales (TTM) | 23.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -157.97% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.